House User Fee Mark-Up: Few Tweaks, But Concerns About ALS And Accelerated Approval

Clinical trial diversity, FDA hiring authority, and inactive ingredient disclosure provisions all get slight modifications. The bill glides through committee, but not without some complaints about agency performance.

Anna Eshoo speaks during Energy and Commerce Committee mark-up
Rep. Anna Eshoo discussed the FDA user fee reauthorization and other bills during a House Energy and Commerce Committee mark-up. • Source: screenshot

Despite concerns from the brand industry, no major changes were made to provisions in the US Food and Drug Administration’s user fee reauthorization bill allowing generic drug sponsors more inactive ingredient information as it breezed to the House floor.

The bill would require the FDA to tell generic drug sponsors whether their products are qualitatively and quantitatively the same...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from User Fees

More from Pathways & Standards